Advances in Tumor Inhibition by Repolarized M2 Macrophages
DOI:
https://doi.org/10.62051/0kqvrz47Abstract
The tumor microenvironment (TME) plays a crucial role in the occurrence, growth, and metastasis of tumors. Tumor-associated macrophages (TAMs), derived from bone marrow precursor cells, exhibit functional plasticity by polarizing into either pro-tumor M2 or anti-tumor M1 phenotypes depending on the microenvironment. This paper explores the advantages and limitations of targeted drug delivery systems using nanocarriers for the repolarization of M2 macrophages into M1 macrophages within the TME. While passive targeted transport techniques allow drug-carrying nanomedicine to selectively accumulate in tumor regions, the efficacy is often hindered by the host's immune response and the inherent toxicity of certain nanomaterials. This review summarizes the current landscape of nanocarriers, emphasizing the need for future research to explore novel nanomaterials and expand the database of drug delivery systems to optimize therapeutic outcomes. Moreover, the potential of polarized macrophage-targeted therapies remains underexplored, suggesting a critical area for future breakthroughs.
Downloads
References
[1] Mohamed F Attia, Nicolas Anton, Justine Wallyn, Ziad Omran, Thierry F Vandamme. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. Journal of Pharmacy and Pharmacology, 2019, 71(8):1185-1198.
[2] SU Xiao-mei, ZHANG Dan-shen. Advances of Targeted Drug Delivery Based on PEG-PCL. Acta Neuropharmacologica, 2016, 6(5):22-28.
[3] WANG Chenchen, DU Chao, GUO Xueling, ZHANG Xiyue, WANG Yingze. Research Progress of Nano-drug Delivery System Targeting Tumor-associated Macrophage in Cancer Treatment. Cancer Research on Prevention and Treatment, 2021, 48(3):307-313.
[4] Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 2022, 27(4):1372.
[5] Begines B, Ortiz T, Pérez-Aranda M, Martínez G, Merinero M, Argüelles-Arias F, Alcudia A. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials (Basel), 2020, 10(7):1403.
[6] Chandrakala V, Aruna V, Angajala G. Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Materials, 2022, 5(6):1593-1615.
[7] Singh S, Hasan M R, Sharma P, et al. Graphene nanomaterials: The wondering material from synthesis to applications. Sensors International, 2022, 3:100190.
[8] Han S, Sun J, He S, Tang M, Chai R. The application of graphene-based biomaterials in biomedicine. American Journal of Translational Research, 2019, 11(6):3246-3260.
[9] Kuppusamy P, Yusoff MM, Maniam GP, Govindan N. Biosynthesis of metallic nanoparticles using plant derivatives and their new avenues in pharmacological applications - An updated report. Saudi Pharmaceutical Journal, 2016, 24(4):473-484.
[10] TAO Linlin, HUO Meirong, XU Wei. Advances in the research of protein nanocarrier materials. Journal of China Pharmaceutical University, 2020, 51(2):121-129.
[11] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022, 39(3):633-638.
[12] Ning P, Du F, Wang H, et al. Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy[J]. Journal of Controlled Release, 2024, 367: 697-707.
[13] Kutova OM, Guryev EL, Sokolova EA, Alzeibak R, Balalaeva IV. Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. Cancers (Basel), 2019, 11(1):68.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
